X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RG6107 (crovalimab) is an investigational, novel anti-C5 recycling monoclonal antibody designed to block the complement system which plays a vital part of the innate immune system that acts as the body’s first line of defence against infection.
Lead Product(s): Crovalimab
Therapeutic Area: Rare Diseases and Disorders Product Name: RG6107
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
PATHWAY anti-HER2 test is only FDA approved companion diagnostic indicated as an aid in assessment of HER2 low status in metastatic breast cancer patients, who may consider ENHERTU (fam-trastuzumab deruxtecan-nxki) as a treatment option based on results of Phase 3 trial.
Lead Product(s): Deruxtecan
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
The VENTANA PD-L1 (SP263) Assay as a companion diagnostic helps determine which patients with non-small cell lung cancer may be eligible for treatment with Libtayo monotherapy based on the results of the Phase III EMPOWER-Lung 1 study.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
The VENTANA MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (dMMR), and who may be eligible for KEYTRUDA® (pembrolizumab).
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.
Lead Product(s): Nangibotide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Inotrem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
